Stem Cell Transplantation Alert Sample


Alert Sample

Alert results for: Stem Cell Transplantation

Information between 2nd September 2024 - 12th September 2024

Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.


Non-Departmental Publications - Transparency
Sep. 10 2024
NHS Blood and Transplant
Source Page: NHS Blood and Transplant annual report and accounts: 2023 to 2024
Document: (PDF)
Transparency

Found: Stem cell transplantation plays a vital role in treating certain blood and metabolic conditions, including

Sep. 10 2024
NHS Blood and Transplant
Source Page: NHS Blood and Transplant annual report and accounts: 2023 to 2024
Document: (PDF)
Transparency

Found: Stem cell transplantation plays a vital role in treating certain blood and metabolic conditions, including



Arms Length Bodies Publications
Sep. 11 2024
NICE
Source Page: Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over
Publication Type: Expected publication
Document: Managed access agreement (PDF 447 KB) (webpage)
Published

Found: Subject to Notice of rights . 14 of 27 • Exposure, such as the date of the haematopoietic stem

Sep. 11 2024
NICE
Source Page: Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over
Publication Type: Education
Document: Managed access agreement (PDF 2.7 MB) (webpage)
Published

Found: Subject to Notice of rights. 14 of 27 •Exposure, such as the date of the haematopoietic stem cell transplantation

Sep. 05 2024
NICE
Source Page: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]
Publication Type: Draft guidance
Document: Draft guidance (downloadable version) PDF 331 KB (webpage)
In consultation

Found: that there is an unmet need for additional treatment options for older people who are ineligible for stem

Sep. 05 2024
NICE
Source Page: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]
Publication Type: Draft guidance
Document: Committee papers PDF 8.97 MB (webpage)
In consultation

Found: Allogeneic stem cell transplantation for myelofibrosis patients aged >/=6 5 years.

Sep. 05 2024
NICE
Source Page: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]
Publication Type: Draft guidance
Document: Public committee slides PDF 1.04 MB (webpage)
In consultation

Found: stakeholder highlighted unmet need for additional treatment options in older patients who are ineligible for stem

Sep. 05 2024
NICE
Source Page: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115]
Publication Type: Draft guidance
Document: Equality impact assessment (downloadable version) PDF 121 KB (webpage)
In consultation

Found: that there is an unmet need for additional treatment options for older people who are ineligible for stem

Aug. 08 2024
NICE
Source Page: Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over
Publication Type: Final draft guidance
Document: Final draft guidance (PDF 342 KB) (webpage)
Published

Found: transfusion -dependent β-thalassemia in patients 12 years of age and older for whom haematopoietic stem

Aug. 08 2024
NICE
Source Page: Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over
Publication Type: Final draft guidance
Document: Managed Access Agreement (PDF 498 KB) (webpage)
Published

Found: Subject to Notice of rights . 14 of 27 • Exposure, such as the date of the haematopoietic stem

Sep. 26 2023
NICE
Source Page: Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment
Publication Type: Invitation to participate
Document: NICE's response to comments on the draft scope and provisional stakeholder list (PDF 202 KB) (webpage)
Published

Found: • As highlighted in the ESMO guidelines, autologous stem cell transplantation may be considered

Sep. 26 2023
NICE
Source Page: Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment
Publication Type: Invitation to participate
Document: Final scope (PDF 181 KB) (webpage)
Published

Found: Chapter 29: Haematopoietic stem cell transplantation services (adults and children) and Chapter 105

Aug. 22 2023
NICE
Source Page: Iptacopan for treating paroxysmal nocturnal haemoglobinuria
Publication Type: Invitation to participate
Document: Final scope (PDF 173 KB) (webpage)
Published

Found: Allogeneic stem cell transplantation may be curative but is associated with significant risks and is

Jul. 26 2023
NICE
Source Page: Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment
Publication Type: Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5085
Document: Draft scope post referral (PDF 214 KB) (webpage)
Published

Found: Stem cell transplantation may also be considered and s plenectomy can be considered for splenic marginal

May. 24 2023
NICE
Source Page: Iptacopan for treating paroxysmal nocturnal haemoglobinuria
Publication Type: Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6176
Document: Draft scope post referral (PDF 180 KB) (webpage)
Published

Found: Allogeneic stem cell transplantation may be curative but is associated with significant risks and is

Apr. 25 2023
NICE
Source Page: Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over
Publication Type: Invitation to participate
Document: Draft scope and provisional stakeholder list comments table (post-referral) (PDF 770 KB) (webpage)
Published

Found: As such, allogenic stem cell transplantation has been removed as a comparator .

Apr. 25 2023
NICE
Source Page: Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over
Publication Type: Invitation to participate
Document: Final scope (PDF 169 KB) (webpage)
Published

Found: Angelucci E, Matthes -Martin S, Baronciani D et al. (2014) Hematopoietic stem cell transplantation

Jan. 19 2023
NICE
Source Page: Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over
Publication Type: Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4015
Document: Draft scope post referral (PDF 172 KB) (webpage)
Published

Found: Angelucci E, Matthes -Martin S, Baronciani D et al. (2014) Hematopoietic stem cell transplantation